

Request Information

Permalink

Improvement Of Glycemic Control Through Beta-Cell Administration Of Mir192

Tech ID: 34404 / UC Case 2022-040-0

TECHNOLOGY DESCRIPTION

Improvement of glycemic control through beta-cell administration of Mir192. Despite the clinical benefits of GLP1R agonists, adverse effects such as gastrointestinal symptoms (nausea, diarrhea, and vomiting) significantly limit drug tolerability in some individuals. These have been attributed to GLP1R activation in the hypothalamus. Thus, development of a novel therapeutic that can specifically upregulate b-cell GLP1R levels could significantly amplify the efficacy of GLP1R agonists, enabling use of lower, more tolerable, doses without impacting efficacy for glycemic maintenance in patients with diabetes who have impaired (but not absent) b-cell function.

STAGE OF DEVELOPMENT

proof of concept

RELATED MATERIALS

► [MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin Secretion](#) - 03/19/2025

PATENT STATUS

Patent Pending

CONTACT

Catherine Smith
Catherine.Smith2@ucsf.edu
tel: [510-646-0631](tel:510-646-0631).



OTHER INFORMATION

CATEGORIZED AS

- [Biotechnology](#)
- [Health](#)
- [Medical](#)
- [Disease:](#)
[Autoimmune and Inflammation](#)
- [Therapeutics](#)

RELATED CASES

2022-040-0